>Markt für Bronchiektasien im asiatisch-pazifischen Raum, nach Krankheitstyp (CF-Bronchiektasien und Nicht-CF-Bronchiektasien), Schweregrad (leicht bis mittelschwer und mittelschwer bis schwer), Typ (Diagnose und Behandlung), Arzneimitteltyp (Marken- und Generika), Verabreichungsweg (oral, parenteral und Inhalation), Endverbraucher (Krankenhäuser, Kliniken, häusliche Pflege und andere), Vertriebskanal (Krankenhausapotheke, Einzelhandelsapotheke, Online-Apotheke, andere), Land (Japan, China, Australien, Indien, Südkorea, Singapur, Indonesien, Thailand, Malaysia, Philippinen, Vietnam und Rest des asiatisch-pazifischen Raums) Branchentrends und Prognose bis 2028
Marktanalyse und Einblicke: Bronchiektasiemarkt im asiatisch-pazifischen Raum
Der Markt für Bronchiektasien im asiatisch-pazifischen Raum wird im Prognosezeitraum 2021 bis 2028 voraussichtlich an Marktwachstum gewinnen. Data Bridge Market Research analysiert, dass der Markt im Prognosezeitraum 2021 bis 2028 mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 6,5 % wächst und bis 2028 voraussichtlich 186,19 Millionen USD erreichen wird. Der technologische Fortschritt bei der Krankheitstestung sowie die steigende Zahl der Raucher und des Alkoholkonsums sind die Haupttreiber, die die Nachfrage des Marktes im Prognosezeitraum ankurbelten.
Bronchiektasie weist Merkmale auf, wie z. B. einen steigenden Bedarf an sicheren und wirksamen Produkten, der die Markteinführung neuer Produkte durch die Hersteller beeinflussen wird, was die Nachfrage steigert, sowie steigende Investitionen in Forschung und Entwicklung, die zu einem Marktwachstum führen. Derzeit finden verschiedene Forschungsstudien statt, die den Herstellern einen Wettbewerbsvorteil bei der Entwicklung neuer und innovativer Bronchiektasieprodukte verschaffen sollen, was voraussichtlich verschiedene andere Möglichkeiten auf dem Bronchiektasiemarkt bieten wird. Produktrückrufe und Komplikationen bei der Behandlung von Bronchiektasie dürften das Marktwachstum im Prognosezeitraum jedoch bremsen.
Bronchiektasien sind Erkrankungen, die zu einer Schädigung der Atemwege der Lunge führen. Dabei kommt es zu Infektionen und Entzündungen in den Ein- und Ausströmwegen der Luft. Der Schleim sammelt sich in den Atemwegen, die dadurch verstopft werden, und Bakterien beginnen sich in diesem Bereich zu vermehren, was zu Bronchiektasien führt. Wenn sich dieser Schleim in den Atemwegen sammelt und nicht frühzeitig diagnostiziert und behandelt wird, kann dies zu Lungenschäden führen. Diese Erkrankung tritt hauptsächlich bei Frauen auf. In den USA wurde festgestellt, dass Kinder mit Keuchhusten im Allgemeinen an Bronchiektasien leiden.
Bronchiektasien können angeboren oder erworben sein. Die erworbenen Bronchiektasien treten vor allem bei Säuglingen und Kindern auf, während die angeborenen Bronchiektasien bei Erwachsenen auftreten. Mukoviszidose , Immundefizienz-Erkrankungen, allergische bronchopulmonale Aspergillose und primäre Ziliendyskinesie sind einige der Risikofaktoren für Bronchiektasien. Die Ärzte verschreiben hauptsächlich Antibiotika und Sauerstofftherapien, und die Patienten müssen mit dem Zustand leben, da es keine dauerhafte Heilung für die Krankheit gibt.
Der Bronchiektasie-Marktbericht enthält Einzelheiten zu Marktanteilen, neuen Entwicklungen und Produktpipeline-Analysen, Auswirkungen inländischer und lokaler Marktteilnehmer, analysiert Chancen in Bezug auf neu entstehende Umsatzbereiche, Änderungen der Marktvorschriften , Produktzulassungen, strategische Entscheidungen, Produkteinführungen, geografische Expansionen und technologische Innovationen auf dem Markt. Um die Analyse und das Marktszenario zu verstehen, kontaktieren Sie uns für ein Analystenbriefing. Unser Team hilft Ihnen dabei, eine Umsatzauswirkungslösung zu entwickeln, mit der Sie Ihr gewünschtes Ziel erreichen.
Marktumfang und Marktgröße für Bronchiektasien im asiatisch-pazifischen Raum
Der Markt für Bronchiektasien ist segmentiert auf der Grundlage von Krankheitstyp, Schweregrad, Art, Arzneimitteltyp, Verabreichungsweg, Endverbraucher und Vertriebskanal. Das Wachstum zwischen den Segmenten hilft Ihnen bei der Analyse von Wachstumsnischen und Strategien zur Marktbearbeitung und bei der Bestimmung Ihrer wichtigsten Anwendungsbereiche und der Unterschiede in Ihren Zielmärkten.
- Auf der Grundlage des Krankheitstyps wird der Bronchiektasiemarkt in Nicht-CF-Bronchiektasie und CF-Bronchiektasie segmentiert. Im Jahr 2021 wird erwartet, dass Nicht-CF-Bronchiektasie den Bronchiektasiemarkt dominieren wird, da es sich um die häufigste Form der Bronchiektasie handelt, von der Berichten zufolge die meisten Frauen und Erwachsenen betroffen sind.
- Auf der Grundlage des Schweregrads wird der Markt für Bronchiektasien in leicht bis mittelschwer und mittelschwer bis schwer unterteilt. Im Jahr 2021 wird das Segment leicht bis mittelschwer voraussichtlich den Markt für Bronchiektasien dominieren, da Bronchiektasien eine fortschreitende Atemwegserkrankung sind, die durch abnorm erweiterte Atemwege, übermäßige Auswurfproduktion und wiederkehrende Lungeninfektionen sowie andere Symptome gekennzeichnet ist, die mit neuartigen Medikamenten und anderen Therapien behandelt werden können.
- Der Markt für Bronchiektasien ist nach Art in Behandlung und Diagnose unterteilt. Im Jahr 2021 wird das Behandlungssegment voraussichtlich den Bronchiektasienmarkt dominieren, da es sich bei Bronchiektasien um eine langfristige chronische Erkrankung handelt und die betroffene Patientengruppe weitgehend auf Medikamente angewiesen ist, um ein gesundes Leben zu führen.
- Auf der Grundlage der Medikamentenart wird der Bronchiektasiemarkt in Marken- und Generika segmentiert . Im Jahr 2021 wird das Markensegment voraussichtlich den Bronchiektasiemarkt dominieren, da die meisten Unternehmen Markenmedikamente herstellen. Darüber hinaus erhöht die steigende Nachfrage nach sicheren Produkten die Nachfrage nach Markenmedikamenten bei der Patientenbevölkerung.
- Auf der Grundlage der Verabreichungsart ist der Markt für Bronchiektasien in orale, parenterale und Inhalation unterteilt. Im Jahr 2021 wird das Inhalationssegment voraussichtlich den Bronchiektasienmarkt dominieren, da Bronchiektasien eine mit der Lunge verbundene entzündliche Erkrankung sind, die schnell mit Medikamenten behandelt werden kann, die direkt auf die Atemwege der Lunge abzielen.
- Auf der Grundlage des Endverbrauchers ist der Bronchiektasiemarkt in Krankenhäuser , Kliniken, häusliche Pflege und andere unterteilt. Im Jahr 2021 dominiert das Krankenhaussegment den Bronchiektasiemarkt, da Krankenhäuser über fortschrittliche Diagnoseinstrumente verfügen, die für eine genaue Diagnose von Bronchiektasie verwendet werden. Darüber hinaus ermöglichen qualifizierte Fachkräfte in Krankenhäusern eine wirksame intravenöse Verabreichung von Medikamenten, was ein weiterer Faktor ist, der das Marktwachstum ankurbelt.
- Auf der Grundlage des Vertriebskanals ist der Bronchiektasiemarkt in Krankenhausapotheken, Einzelhandelsapotheken und Online-Apotheken segmentiert. Im Jahr 2021 wird die Krankenhausapotheke voraussichtlich den Bronchiektasiemarkt dominieren, da Krankenhausapotheken eine breite Produktpalette entsprechend den Bedürfnissen und der Nachfrage der Patienten haben.
Bronchiektasie Markt – Länderebene Analyse
Der Markt für Bronchiektasien wird analysiert und Informationen zur Marktgröße werden auf Grundlage von Krankheitstyp, Schweregrad, Art, Arzneimitteltyp, Verabreichungsweg, Endverbraucher und Vertriebskanal bereitgestellt.
Die im Marktbericht zu Bronchiektasien abgedeckten Länder sind Japan, China, Australien, Indien, Südkorea, Singapur, Indonesien, Thailand, Malaysia, die Philippinen, Vietnam und der restliche asiatisch-pazifische Raum.
Das Behandlungssegment im asiatisch-pazifischen Raum wird im Prognosezeitraum von 2021 bis 2028 voraussichtlich die höchste Wachstumsrate aufweisen, da Bronchiektasien eine lebenslange Krankheit sind und eine kontinuierliche Behandlung erfordern. Die Gesamtbehandlungskosten für Bronchiektasien sind recht hoch und werden mittlerweile in einigen Erstattungsrichtlinien berücksichtigt. Japan ist führend beim Wachstum des asiatisch-pazifischen Marktes und das Behandlungssegment dominiert in diesem Land aufgrund des technologischen Fortschritts bei der Diagnose und Behandlung von Atemwegserkrankungen.
Der Länderabschnitt des Berichts enthält auch Angaben zu einzelnen marktbeeinflussenden Faktoren und Änderungen der Regulierung auf dem Inlandsmarkt, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neuverkäufe, Ersatzverkäufe, demografische Daten des Landes, Regulierungsgesetze und Import-/Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit von Marken aus dem asiatisch-pazifischen Raum und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen der Vertriebskanäle berücksichtigt.
Technologischer Fortschritt bei Krankheitstests und zunehmende Forschung in Bezug auf die Bronchiektasie-Krankheit fördern das Marktwachstum der Bronchiektasie
Der Bronchiektasiemarkt bietet Ihnen außerdem eine detaillierte Marktanalyse für jedes Land, in dem die Bronchiektasiebranche wächst, mit Angaben zum Umsatz mit Bronchiektasiemedikamenten, den Auswirkungen des Fortschritts in der Bronchiektasietechnologie und Änderungen in regulatorischen Szenarien mit ihrer Unterstützung für den Bronchiektasiemarkt. Die Daten sind für den historischen Zeitraum 2011 bis 2019 verfügbar.
Wettbewerbsumfeld und Bronchiektasie Marktanteilsanalyse
Die Wettbewerbslandschaft des Bronchiektasie-Marktes liefert Details nach Wettbewerbern. Die enthaltenen Details sind Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Produktionsstandorte und -einrichtungen, Stärken und Schwächen des Unternehmens, Produkteinführung, Produkttestpipelines, Produktzulassungen, Patente, Produktbreite und -breite, Anwendungsdominanz, Technologie-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens in Bezug auf den Bronchiektasie-Markt.
Die wichtigsten Unternehmen, die sich mit Bronchiektasien befassen, sind unter anderem Abbott, HERSILL, Inogen, Inc., Boehringer Ingelheim International GmbH, Medline Industries, Inc, Ache Laboratories Farmaceuticos SA, Janssen Pharmaceuticals, Inc. (eine Tochtergesellschaft von Johnson & Johnson Services, Inc.), GlaxoSmithKline plc., AstraZeneca, Pfizer Inc., Merck Sharp & Dohme Corp., eine Tochtergesellschaft von Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Bayer AG, Dr. Reddy's Laboratories Ltd., Viatris Inc. und Cipla Inc.
Darüber hinaus werden von den Unternehmen weltweit zahlreiche Produkteinführungen und Vereinbarungen initiiert, die den Bronchiektasie-Markt ebenfalls ankurbeln.
- Im Dezember 2018 erhielt AstraZeneca die Zulassung für Bevespi Aerosphere (Glycopyrronium/Formoterolfumarat) zur Behandlung schwerer Symptome im Zusammenhang mit COPD. Dieses Produkt wurde bereits von den Aufsichtsbehörden in Kanada, den USA, Australien, Taiwan und der Türkei zugelassen. Diese neue Zulassung steigerte den Produktabsatz, was sich positiv auf den Umsatz des Unternehmens auswirkte.
- Im Februar 2018 brachte GlaxoSmithKline plc. Flunase in Japan auf den Markt. Flunase ist das erste in Japan auf Fluticasonpropionat basierende Medikament und soll die mit Atemproblemen verbundenen Entzündungssymptome lindern. Mit dieser Produkteinführung konnte das Unternehmen den ungedeckten Bedarf japanischer Patienten mit Bronchiektasien decken und den Umsatz des Unternehmens durch eine positive Steigerung der Produktverkäufe steigern.
Zusammenarbeit, Produkteinführung, Geschäftsausweitung, Auszeichnungen und Anerkennung, Joint Ventures und andere Strategien der Marktteilnehmer stärken den Unternehmensmarkt im Bronchiektasie-Markt, was den Unternehmen auch den Vorteil bietet, ihr Angebot zur Behandlung von Bronchiektasien zu verbessern.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC BRONCHIECTASIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET DRUGS TYPE COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 ASIA PACIFIC BRONCHIECTASIS MARKET: LAWS AND REGULATIONS
6 EPIDEMIOLOGY
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS
7.1.2 GROWING GERIATRIC POPULATION
7.1.3 RISING NUMBER OF SMOKERS AND CONSUMPTION OF ALCOHOL
7.1.4 TECHNOLOGICAL ADVANCEMENT FOR DISEASE TESTING
7.1.5 GROWING DIAGNOSTIC RATE
7.2 RESTRAINTS
7.2.1 HIGH COST OF DIAGNOSTIC TOOLS
7.2.2 PRODUCT RECALLS
7.2.3 INAPPROPRIATE REIMBURSEMENT POLICIES
7.3 OPPORTUNITIES
7.3.1 RISING AWARENESS FOR PREVENTION OF BRONCHIECTASIS IN PRIMARY AND SECONDARY CARE
7.3.2 INCREASING HEALTHCARE EXPENDITURE
7.3.3 INCREASE IN RESEARCH REGARDING THE BRONCHIECTASIS DISEASE
7.3.4 AVAILABILITY OF GENERIC DRUGS IN UNDERDEVELOPED AND DEVELOPING COUNTRIES
7.4 CHALLENGES
7.4.1 COMPLICATIONS IN THE TREATMENT OF BRONCHIECTASIS
7.4.2 LACK OF SKILLED PROFESSIONALS
7.4.3 DIAGNOSITIC CHALLENGES
8 IMPACT OF COVID-19
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 NON-CF BRONCHIECTASIS
9.3 CF BRONCHIECTASIS
10 ASIA PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY
10.1 OVERVIEW
10.2 MILD TO MODERATE
10.3 MODERATE TO SEVERE
11 ASIA PACIFIC BRONCHIECTASIS MARKET, BY TYPE
11.1 OVERVIEW
11.2 TREATMENT
11.2.1 ANTIBIOTICS
11.2.1.1 MACROLIDE
11.2.1.1.1 AZITHROMYCIN
11.2.1.1.2 CLARITHROMYCIN
11.2.1.1.3 OTHERS
11.2.1.2 AMOXICILLIN
11.2.1.3 CEPHALOSPORIN
11.2.1.3.1 SECOND-GENERATION CEPHALOSPORIN
11.2.1.3.2 THIRD-GENERATION CEPHALOSPORIN
11.2.1.4 AMINOGLYCOSIDE
11.2.1.4.1 GENTAMICIN
11.2.1.4.2 TOBRAMYCIN
11.2.1.5 FLUOROQUINOLONE
11.2.1.6 TETRACYCLINS
11.2.1.7 TRIMETHOPRIM-SULFAMETHOXAZOLE
11.2.1.8 COMBINATION THERAPY
11.2.2 CORTICOSTEROIDS
11.2.2.1 BUDESONIDE
11.2.2.2 FLUTICASONE
11.2.2.3 MOMETASONE
11.2.2.4 FLUNISOLIDE
11.2.2.5 OTHERS
11.2.3 BRONCHODILATORS
11.2.3.1 LONG-ACTING BRONCHODILATORS
11.2.3.1.1 FORMOTEROL
11.2.3.1.2 TIOTROPIUM
11.2.3.1.3 SALMETEROL
11.2.3.1.4 OTHERS
11.2.3.2 SHORT-ACTING BRONCHODILATORS
11.2.3.2.1 ALBUTEROL
11.2.3.2.2 LEVALBUTEROL
11.2.3.2.3 OTHERS
11.2.4 MUCUS THINNING MEDICINE
11.2.4.1 CARBOCISTEINE
11.2.4.2 BROMHEXINE
11.2.4.3 OTHERS
11.2.5 AIRWAY CLEARANCE DEVICES
11.2.5.1 OSCILLATING POSITIVE EXPIRATORY PRESSURE (PEP)
11.2.5.2 INTRAPULMONARY PERCUSSIVE VENTILATION (IPV)
11.2.5.3 POSTURAL DRAINAGE
11.2.5.4 OTHERS
11.2.6 OXYGEN THERAPY
11.2.6.1 OXYGEN CONCENTRATORS
11.2.6.2 COMPRESSED GAS OXYGEN
11.2.6.3 LIQUID OXYGEN
11.2.7 SURGERY
11.2.7.1 BRONCHOSCOPY
11.2.7.2 LUNG TRANSPLANT
11.2.8 OTHERS
11.3 DIAGNOSIS
11.3.1 CHEST CT SCAN
11.3.2 SPUTUM TEST
11.3.3 PULMONARY FUNCTION TEST
11.3.4 X-RAY
11.3.5 OTHERS
12 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 BRANDED
12.3 GENERICS
13 ASIA PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 INHALATION
13.3 ORAL
13.3.1 TABLETS
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 PARENTERAL
13.4.1 INTRAVENOUS
13.4.2 SUBCUTANEOUS
13.4.3 OTHERS
14 ASIA PACIFIC BRONCHIECTASIS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE PHARMACY
15.5 OTHERS
16 ASIA PACIFIC BRONCHIECTASIS MARKET BY GEOGRAPHY
16.1 OVERVIEW
16.2 ASIA-PACIFIC
16.2.1 JAPAN
16.2.2 CHINA
16.2.3 INDIA
16.2.4 AUSTRALIA
16.2.5 SOUTH KOREA
16.2.6 SINGAPORE
16.2.7 MALAYSIA
16.2.8 THAILAND
16.2.9 INDONESIA
16.2.10 PHILIPPINES
16.2.11 VIETNAM
16.2.12 REST OF ASIA-PACIFIC
17 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT
19 COMPANY PROFILES
19.1 ASTRAZENECA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 GLAXOSMITHKLINE PLC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 NOVARTIS AG
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 ABBOTT
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 ACHE LABORATORIES FARMACEUTICOS S.A.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 BAYER AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 COVIS PHARMA
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 DR. REDDY’S LABORATORIES LTD.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 ELECTROMED, INC.
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 HERSILL
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 HOME OXYGEN COMPANY
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 HORIZON THERAPEUTICS PLC
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 INOGEN, INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 MEDLINE INDUSTRIES, INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 PFIZER INC.
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 SUNOVION PHARMACEUTICALS INC. (A SUBSIDIARY OF SUMITOMO DAINIPPON PHARMA CO., LTD.)
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
19.23 TRUEDELL MEDICAL INTERNATIONAL
19.23.1 COMPANY SNAPSHOT
19.23.2 PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENTS
19.24 VIATRIS INC.
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
19.25 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
19.25.1 COMPANY SNAPSHOT
19.25.2 REVENUE ANALYSIS
19.25.3 PRODUCT PORTFOLIO
19.25.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Tabellenverzeichnis
LIST OF TABLES
TABLE 1 ASIA PACIFIC BRONCHIECTASIS MARKET, PIPELINE ANALYSIS
TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS
TABLE 3 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
TABLE 4 THE PRICE OF X-RAY MACHINE
TABLE 5 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 6 ASIA PACIFIC NON-CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA PACIFIC CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 9 ASIA PACIFIC MILD TO MODERATE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA PACIFIC MODERATE TO SEVERE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA PACIFIC BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 ASIA PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 13 ASIA PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 ASIA PACIFIC TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 ASIA PACIFIC TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 ASIA PACIFIC TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 ASIA PACIFIC TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 ASIA PACIFIC TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 ASIA PACIFIC TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 ASIA PACIFIC TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 ASIA PACIFIC TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 ASIA PACIFIC TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 23 ASIA PACIFIC TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 24 ASIA PACIFIC TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 ASIA PACIFIC TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 ASIA PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 29 ASIA PACIFIC BRANDED IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA PACIFIC GENERICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC INHALATION IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 ASIA PACIFIC ORAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 ASIA PACIFIC PARENTERAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 ASIA PACIFIC PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC BRONCHIECTASIS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 ASIA PACIFIC HOSPITALS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 ASIA PACIFIC CLINICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 ASIA PACIFIC HOME HEALTHCARE IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 ASIA PACIFIC OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFIC HOSPITAL PHARMACY IN BRONCHIECTASIS MARKET, REGION, 2019-2028 (USD MILLION)
TABLE 44 ASIA PACIFIC RETAIL PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 ASIA PACIFIC ONLINE PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 ASIA PACIFIC OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 ASIA PACIFIC BRONCHIECTASIS MARKET, BY REGION , 2021-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 ASIA-PACIFIC TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 ASIA-PACIFIC TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 ASIA-PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 67 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 ASIA-PACIFIC ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 ASIA-PACIFIC PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 71 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 72 JAPAN BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 73 JAPAN BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 74 JAPAN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 JAPAN TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 JAPAN TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 JAPAN TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 JAPAN TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 JAPAN TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 JAPAN TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 JAPAN TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 JAPAN TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 JAPAN TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 JAPAN TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 JAPAN TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 JAPAN TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 JAPAN TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 JAPAN DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 JAPAN BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 90 JAPAN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 91 JAPAN ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 92 JAPAN PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 93 JAPAN BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 94 JAPAN BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 CHINA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 96 CHINA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 97 CHINA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 CHINA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 99 CHINA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 100 CHINA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 101 CHINA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 CHINA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 CHINA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 CHINA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 CHINA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 CHINA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 CHINA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 CHINA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 CHINA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 CHINA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 CHINA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 CHINA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 113 CHINA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 114 CHINA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 115 CHINA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 116 CHINA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 117 CHINA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 118 INDIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 119 INDIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 120 INDIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 INDIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 INDIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 INDIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 124 INDIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 INDIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 INDIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 INDIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 INDIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 INDIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 INDIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 INDIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 INDIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 INDIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 INDIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 INDIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 136 INDIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 137 INDIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 138 INDIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 139 INDIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 140 INDIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 141 AUSTRALIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 142 AUSTRALIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 143 AUSTRALIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 144 AUSTRALIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 145 AUSTRALIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 146 AUSTRALIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 AUSTRALIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 AUSTRALIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 149 AUSTRALIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 150 AUSTRALIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 151 AUSTRALIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 152 AUSTRALIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 153 AUSTRALIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 AUSTRALIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 AUSTRALIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 AUSTRALIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 AUSTRALIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 AUSTRALIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 159 AUSTRALIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 160 AUSTRALIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 161 AUSTRALIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 162 AUSTRALIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 163 AUSTRALIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 164 SOUTH KOREA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 165 SOUTH KOREAT BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 166 SOUTH KOREA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 167 SOUTH KOREA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 168 SOUTH KOREA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 169 SOUTH KOREA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 170 SOUTH KOREA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 171 SOUTH KOREA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 SOUTH KOREA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 SOUTH KOREA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 SOUTH KOREA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 SOUTH KOREA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 SOUTH KOREA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 SOUTH KOREA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 SOUTH KOREA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 179 SOUTH KOREA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 180 SOUTH KOREA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 181 SOUTH KOREA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 182 SOUTH KOREA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 183 SOUTH KOREA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 SOUTH KOREA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 185 SOUTH KOREA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 186 SOUTH KOREA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 187 SINGAPORE BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 188 SINGAPORE BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 189 SINGAPORE BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 SINGAPORE TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 SINGAPORE TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 SINGAPORE TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 SINGAPORE TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 SINGAPORE TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 SINGAPORE TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 SINGAPORE TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 197 SINGAPORE TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 198 SINGAPORE TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 199 SINGAPORE TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 200 SINGAPORE TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 201 SINGAPORE TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 202 SINGAPORE TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 203 SINGAPORE DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 SINGAPORE BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 205 SINGAPORE BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 206 SINGAPORE ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 207 SINGAPORE PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 208 SINGAPORE BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 209 SINGAPORE BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 210 MALAYSIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 211 MALAYSIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 212 MALAYSIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 213 MALAYSIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 214 MALAYSIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 215 MALAYSIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 216 MALAYSIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 217 MALAYSIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 218 MALAYSIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 219 MALAYSIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 220 MALAYSIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 221 MALAYSIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 222 MALAYSIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 223 MALAYSIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 224 MALAYSIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 225 MALAYSIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 226 MALAYSIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 MALAYSIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 228 MALAYSIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 229 MALAYSIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 230 MALAYSIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 231 MALAYSIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 232 MALAYSIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 233 THAILAND BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 234 THAILAND BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 235 THAILAND BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 236 THAILAND TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 237 THAILAND TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 238 THAILAND TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 239 THAILAND TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 240 THAILAND TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 241 THAILAND TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 242 THAILAND TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 THAILAND TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 244 THAILAND TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 245 THAILAND TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 246 THAILAND TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 247 THAILAND TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 248 THAILAND TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 249 THAILAND DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 250 THAILAND BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 251 THAILAND BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 252 THAILAND ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 253 THAILAND PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 254 THAILAND BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 255 THAILAND BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 256 INDONESIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 257 INDONESIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 258 INDONESIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 259 INDONESIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 260 INDONESIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 261 INDONESIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 262 INDONESIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 263 INDONESIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 264 INDONESIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 265 INDONESIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 266 INDONESIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 267 INDONESIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 INDONESIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 INDONESIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 INDONESIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 271 INDONESIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 272 INDONESIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 273 INDONESIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 274 INDONESIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 275 INDONESIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 276 INDONESIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 277 INDONESIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 278 INDONESIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 279 PHILIPPINES BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 280 PHILIPPINES BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 281 PHILIPPINES BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 282 PHILIPPINES TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 283 PHILIPPINES TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 284 PHILIPPINES TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 285 PHILIPPINES TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 286 PHILIPPINES TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 287 PHILIPPINES TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 288 PHILIPPINES TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 289 PHILIPPINES TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 290 PHILIPPINES TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 291 PHILIPPINES TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 292 PHILIPPINES TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 293 PHILIPPINES TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 294 PHILIPPINES TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 295 PHILIPPINES DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 296 PHILIPPINES BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 297 PHILIPPINES BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 298 PHILIPPINES ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 299 PHILIPPINES PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 300 PHILIPPINES BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 301 PHILIPPINES BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 302 VIETNAM BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 303 VIETNAM BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 304 VIETNAM BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 305 VIETNAM TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 306 VIETNAM TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 307 VIETNAM TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 308 VIETNAM TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 309 VIETNAM TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 310 VIETNAM TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 311 VIETNAM TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 312 VIETNAM TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 313 VIETNAM TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 314 VIETNAM TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 315 VIETNAM TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 316 VIETNAM TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 317 VIETNAM TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 318 VIETNAM DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 319 VIETNAM BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 320 VIETNAM BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 321 VIETNAM ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 322 VIETNAM PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 323 VIETNAM BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 324 VIETNAM BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 325 REST OF ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
Abbildungsverzeichnis
LIST OF FIGURES
FIGURE 1 ASIA PACIFIC BRONCHIECTASIS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC BRONCHIECTASIS MARKET : DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC BRONCHIECTASIS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC BRONCHIECTASIS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC BRONCHIECTASIS MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA PACIFIC BRONCHIECTASIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA PACIFIC BRONCHIECTASIS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC BRONCHIECTASIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC BRONCHIECTASIS MARKET: MARKET DRUGS TYPE COVERAGE GRID
FIGURE 11 ASIA PACIFIC BRONCHIECTASIS MARKET: SEGMENTATION
FIGURE 12 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS IS DRIVING THE ASIA PACIFIC BRONCHIECTASIS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 NON-CF BRONCHIECTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC BRONCHIECTASIS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC BRONCHIECTASIS MARKET
FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050
FIGURE 16 PREVALENCE OF BRONCHIECTASIS BY AGE IN KOREA POPULATION (2019)
FIGURE 17 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS
FIGURE 18 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2021
FIGURE 19 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION)
FIGURE 20 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 21 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, 2021
FIGURE 23 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, 2019-2028 (USD MILLION)
FIGURE 24 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, CAGR(2021-2028)
FIGURE 25 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, 2021
FIGURE 27 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 28 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 29 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2021
FIGURE 31 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2019-2028 (USD MILLION)
FIGURE 32 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, CAGR (2021-2028)
FIGURE 33 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 34 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 35 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 36 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 37 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 38 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, 2021
FIGURE 39 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 40 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 41 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 43 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 44 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 45 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 46 ASIA PACIFIC BRONCHIECTASIS MARKET: SNAPSHOT (2020)
FIGURE 47 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020)
FIGURE 48 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 49 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 50 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 51 ASIA-PACIFIC BRONCHIECTASIS MARKET: SNAPSHOT (2020)
FIGURE 52 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020)
FIGURE 53 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 54 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 55 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 56 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
